ePT--the Electronic Newsletter of Pharmaceutical Technology, Jun 30, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Jun 30, 2011
News
Obama Initiates Partnership to Reinvigorate Manufacturing
By Erik Greb
President Obama unveiled an Advanced Manufacturing Partnership designed to reinvigorate the country's manufacturing sector.
IPEC Federation Issues Statement of Phthalate Use
By Patricia Van Arnum
The IPEC Federation has issued a statement on the use of phthalates in pharmaceutical products in response to reports of adulteration of certain nutritional supplements, vitamins, foods, and beverages imported from Taiwan.
EMA Stakeholder Forum on Pharmacovigilance
By Rich Whitworth
The European Medicines Agency (EMA) has held a second forum regarding the implementation of new pharmacovigilance legislation, which gave stakeholders the opportunity to discuss their expectations on various aspects of the new legislation's execution.
Pharma R&D Concerns
By Stephanie Sutton
Industry analysts have highlighted the pharma industry's high rate of Phase III drug terminations and significantly reduced R&D spending.
Week of June 27, 2011: Company and People Notes: Roche Establishes R&D Institute in France; Sanofi Appoints Peter Guenter as Senior Vice-President, Europe; and More.
Roche Establishes R&D Institute in France; Sanofi Appoints Peter Guenter as Senior Vice-President, Europe; and More.
Regulatory Roundup: FDA Publishes Final Guidance on Dissolution Testing
FDA Publishes Final Guidance on Dissolution Testing.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here